Shots:
- The P-I/II Stellar trial involve assessing QR-421a in 20 patients with usher syndrome and non-syndromic retinitis pigmentosa (nsRP) due to USH2A exon 13 mutations for 24mos.
- Results: QR-421 demonstrated benefit on multiple measures of vision, including best-corrected visual activity (BCVA), static perimetry, and retinal imaging (OCT) and was well-tolerated with no observed SAEs and inflammation
- The company plans to initiate two pivotal P-II/III trials in early-moderate and advanced patients by the end of 2021
Click here to read full press release/ article | Ref: ProQR | Image: EyeWire News
The post ProQR Reports Results of QR-421 in P-I/II Stellar Trial for Usher Syndrome first appeared on PharmaShots.
